Alnylam Pharmaceuticals
- ALNY
- NASDAQ
- Consumer Products
- Latest 27.56
- Currency US$
- Change 0.12
- Percent Change 0.437 %
- Volume 259,369
- Mon May 20, 2013 4:00 PM EDT NASDAQ data delayed 15 minutes.
The Globe and Mail
- Open 27.24
- Previous Close 27.44
- High 27.75
- Low 27.24
- Bidx0 --
- Askx0 --
- 52-week High 05/14 28.68
- 52-week Low 05/18 9.51
- Beta 1.45
- Market Cap 1,705.14M
- EPS -1.24
- P/E --
- Forward P/E --
- PEG --
- Annual Dividend --
- Yield --
News
- Alnylam Presents Key Pre-Clinical Proof-of-Concept Data for ALN-AS1, an RNAi Therapeutic Targeting Aminolevulinate Synthase-1 (ALAS-1) for the Treatment of Porphyria
- Alnylam to Webcast Presentation at 2013 UBS Global Healthcare Conference
- Alnylam to Webcast Presentation at 2013 Bank of America Merrill Lynch Health Care Conference
- Alnylam Pharmaceuticals Reports First Quarter 2013 Financial Results
- Alnylam to Webcast Conference Call Discussing First Quarter 2013 Financial Results
Financials & Calendars
- Sales $64,770,000
- Earnings $-103,660,000
- Return on Equity n/a
- Cash Flow --
- Cash $97,800,000
- Current Ratio 4.83
12 months ended Mar 31, 2013.
Trailing 12 month results shown above.
All data is in U.S. dollars.
- Assets $471,570,000
- Liabilities $160,020,000
- Liabilities-to-Equity Ratio 0.51
Price Ratios
- Price to Sales 26.33
- Price to Book 5.47
- Price to Cash Flow n/a
Event Calendar
| Event | Last | Next | ||
|---|---|---|---|---|
| Earnings | May 6 | $-0.31 | Aug 5 | $-0.34 |
| Surprises | May 6 | -51.61% | n/a | n/a |
| Dividends | n/a | n/a | n/a | n/a |
| Splits | n/a | -- | n/a | n/a |
12 months ended May 21, 2013.
A look at major corporate events and financial announcements that are coming up.
Company Information
About the Company
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus infection, which is the leading cause of hospitalization in infants in the U.S. The company's leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, and Biogen Idec.
Officers
- John M. Maraganore,Ph.D. Director & C.E.O.
- Michael P. Mason Vice President of Finance & Tr
- Company Type: n/a
- Company Status: n/a
- Full-time Employees: n/a
-
Incorporation:
United States,
n/a -
Top 1000 Ranking:
Profit: n/a
Revenue: n/a
Assets: n/a
Head Office
300 THIRD STREETCAMBRIDGE, MA
02142
Phone: (617)-551-8200
Fax: (617)-5518101
Ideas & Discussion
Live Discussion of ALNY on StockTwits